NEJ026: Phase III study comparing bevacizumab plus...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations

Maemondo, M., Fukuhara, T., Sugawara, S., Takiguchi, Y., Inoue, A., Oizumi, S., Ishii, Y., Yoshizawa, H., Isobe, T., Gemma, A., Morita, S., Hagiwara, K., Kobayashi, K., Nukiwa, T.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw383.86
Date:
October, 2016
File:
PDF, 38 KB
english, 2016
Conversion to is in progress
Conversion to is failed